Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3097–3120 of 185,116 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: NOT program Clear all

Conditions: Chronic Hepatitis B
Interventions: Adefovir Dipivoxil for oral suspension, 2 mg/mL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Foster City, California

Conditions: Prostate Cancer
Interventions: Survey Administration; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non Small Cell Lung Cancer
Interventions: Paclitaxel, NOV-002, Carboplatin; Drug
Lead sponsor: Cellectar Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 903 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 12
States / cities: Muscle Shoals, Alabama • San Diego, California • Chicago, Illinois + 9 more

Conditions: Glioblastoma Multiforme
Interventions: CyberKnife; Procedure
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 66 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: Benralizumab; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 52
States / cities: Scottsboro, Alabama • Glendale, Arizona • Phoenix, Arizona + 42 more

Conditions: Meditation, Pain, Mindfulness, Affect, Emotion Regulation
Interventions: Mindfulness-enhanced positive affect induction, Breathing Meditation; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Dry Mouth, Xerostomia, OSA, Sleep Apnea
Interventions: Test Oral Spray, Placebo Oral Spray; Device
Lead sponsor: You First Services; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Human Immunodeficiency Virus Type 1 (HIV-1)
Interventions: Atazanavir, Cobicistat, Atazanavir/Cobicistat FDC; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Acute Pain, Analgesia
Interventions: Placebos, Baclofen 5 mg, Baclofen 10mg; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Migraine, Traumatic Brain Injury, Anomalous Health Incidents
Interventions: Xeomin (incobotulinumtoxinA); Drug
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: abatacept; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 7
States / cities: Anniston, Alabama • Palm Harbor, Florida • Wheaton, Maryland + 4 more

Conditions: Physical Endurance
Interventions: Beta-alanine, Placebo, Muscular endurance exercise; Dietary Supplement · Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 60 Years to 90 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease, SARS (Disease)
Interventions: BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7), Monovalent BNT162b2 (B.1.617.2), Monovalent BNT162b2 (B.1.1.529.1), Observational; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,380 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 14
States / cities: Long Beach, California • San Diego, California • Milford, Connecticut + 10 more

Conditions: Healthy Males
Interventions: Acyline, placebo hCG (no active ingredient), hCG (human chorionic gonadotropin), Testosterone gel; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Primary Biliary Cholangitis
Interventions: Seladelpar 10 mg, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 43
States / cities: Chandler, Arizona • Pasadena, California • Sacramento, California + 32 more

Conditions: Hypertension
Interventions: Telemonitors and pharmacy management; Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 21 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Osteoarthritis of the Knee
Interventions: Lorecivivint; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 4
States / cities: Tucson, Arizona • Winter Park, Florida • Oak Brook, Illinois + 1 more

Conditions: Healthy
Interventions: Odalasvir 100 mg, Placebo, Odalasvir 500 mg, Odalasvir (Up to maximum 1000 mg); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hyperphosphatemia, End-stage Renal Disease
Interventions: ferric citrate; Drug
Lead sponsor: Keryx Biopharmaceuticals; Industry
Eligibility: 19 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Short Stature
Interventions: Growth Hormone; Drug
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 5 Years to 11 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Parkinson's Disease (PD), Early Onset Parkinson Disease
Interventions: AAV2-hAADC; Drug
Lead sponsor: Russell Lonser; Other
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hematologic Diseases, Anaemia, Sickle Cell
Interventions: GSK4172239D, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Miami, Florida • Tamarac, Florida • Atlanta, Georgia + 3 more

Conditions: Leukemia
Interventions: No Intervention; Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor
Interventions: nilotinib; Drug
Lead sponsor: Andrew J. Wagner, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 7
States / cities: Santa Monica, California • Stanford, California • Tampa, Florida + 3 more

Search by objective public record fields.

Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B

Goals of Sexual Function in Prostate Cancer Survivors and Their Partners After Cancer Treatment

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

Radiosurgery for Glioblastoma Multiforme

A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist

Study of Affect Induction for Lab Induced Pain in Healthy Undergraduates

"Hyaluronan" Formulation for Dry Mouth in Sleep Apnea Patients

Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat

Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers

Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents

A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept

Beta-alanine and Elder Endurance

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone

Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

Home Blood Pressure Telemonitoring and Case Management to Control Hypertension

3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis

A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants

A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)

The Role of Igf-1 Generation Test in Diagnosis and Treatment of Short Stature

AAV2-hAADC for Parkinson's Disease (PDCS-01)

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor